Update on third-generation EGFR tyrosine kinase inhibitors

被引：7
|
作者：
Gray, Jhanelle
Haura, Eric
机构：
[1] H Lee Moffitt Canc Ctr & Res Inst, Dept Thorac Oncol & Chem Biol, Tampa, FL 33612 USA
[2] H Lee Moffitt Canc Ctr & Res Inst, Program Mol Med, Tampa, FL 33612 USA
来源：
TRANSLATIONAL LUNG CANCER RESEARCH | 2014年 / 3卷 / 06期
关键词：
D O I：
10.3978/j.issn.2218-6751.2014.09.08
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：360 / 362
页数：3
相关论文
共 50 条
  • [31] Unique Cutaneous Reaction to Second-and Third-Generation Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia
    Patel, Anisha B.
    Solomon, Alvin R.
    Mauro, Michael J.
    Ehst, Benjamin D.
    DERMATOLOGY, 2016, 232 (01) : 122 - 125
  • [32] Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors
    Ortiz-Cuaran, Sandra
    Scheffler, Matthias
    Plenker, Dennis
    Dahmen, Ilona
    Scheel, Andreas H.
    Fernandez-Cuesta, Lynnette
    Meder, Lydia
    Lovly, Christine M.
    Persigehl, Thorsten
    Merkelbach-Bruse, Sabine
    Bos, Marc
    Michels, Sebastian
    Fischer, Rieke
    Albus, Kerstin
    Koenig, Katharina
    Schildhaus, Hans-Ulrich
    Fassunke, Jana
    Ihle, Michaela A.
    PasternackO, Helen
    Heydt, Carina
    Becker, Christian
    Altmueller, Janine
    Ji, Hongbin
    Mueller, Christian
    Florin, Alexandra
    Heuckmann, Johannes M.
    Nuernberg, Peter
    Ansen, Sascha
    Heukamp, Lukas C.
    Berg, Johannes
    Pao, William
    Peifer, Martin
    Buettner, Reinhard
    Wolfe, Juergen
    Thomas, Roman K.
    Sos, Martin L.
    CLINICAL CANCER RESEARCH, 2016, 22 (19) : 4837 - 4847
  • [33] Unique cutaneous reaction to second- and third-generation tyrosine kinase inhibitors for chronic myeloid leukemia
    Patel, A.
    Solomon, A.
    Mauro, M.
    Ehst, B. D.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 : S44 - S44
  • [34] Acquired resistance to third-generation EGFR-TKIs and emerging next-generation EGFR inhibitors
    Du, Xiaojing
    Yang, Biwei
    An, Quanlin
    Assaraf, Yehuda G.
    Cao, Xin
    Xia, Jinglin
    INNOVATION, 2021, 2 (02):
  • [35] Genomic landscape of acquired resistance to third-generation EGFR tyrosine kinase inhibitors in EGFR T790M-mutant non-small cell lung cancer
    Lee, Jiyun
    Kim, Hong Sook
    Lee, Boram
    Kim, Hee Kyung
    Sun, Jong-Mu
    Ahn, Jin Seok
    Ahn, Myung-Ju
    Park, Keunchil
    Lee, Se-Hoon
    CANCER, 2020, 126 (11) : 2704 - 2712
  • [36] Third-generation inhibitors of mTOR
    Shokat, Kevan M.
    CANCER RESEARCH, 2017, 77
  • [37] Structural Differences between Wild-Type and Double Mutant EGFR Modulated by Third-Generation Kinase Inhibitors
    Lowder, Melissa A.
    Doerner, Amy E.
    Schepartz, Alanna
    JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2015, 137 (20) : 6456 - 6459
  • [38] Mechanisms of Resistance to EGFR Tyrosine Kinase Inhibitors and Therapeutic Approaches: An Update
    Ahsan, Aarif
    LUNG CANCER AND PERSONALIZED MEDICINE: CURRENT KNOWLEDGE AND THERAPIES, 2016, 893 : 137 - 153
  • [39] MUSASHI-2 confers resistance to third-generation EGFR-tyrosine kinase inhibitor osimertinib in lung adenocarcinoma
    Yiming, Reheman
    Takeuchi, Yasuto
    Nishimura, Tatsunori
    Li, Mengjiao
    Wang, Yuming
    Meguro-Horike, Makiko
    Kohno, Takashi
    Horike, Shin-ichi
    Nakata, Asuka
    Gotoh, Noriko
    CANCER SCIENCE, 2021, 112 (09) : 3810 - 3821
  • [40] A new generation of EGFR tyrosine-kinase inhibitors in NSCLC
    Hirsch, Fred R.
    Bunn, Paul A., Jr.
    LANCET ONCOLOGY, 2012, 13 (05): : 442 - 443
12345